GE Healthcare acquires Asymptote for safe manufacture and delivery of cellular therapies

The acquisition further strengthens GE Healthcare’s cell therapy portfolio with a suite of technologies for the cryopreservation of cellular materials

9

GE Healthcare has acquired Asymptote Limited, specialists in cryochain technology for sensitive cellular therapies. The acquisition of Asymptote fills a critical gap in GE Healthcare's end-to-end ecosystem of products and services for cell therapy production, and will be an important piece of the portfolio enabling the industrialization of these life-saving therapies. As the cell therapy market develops, demand for manufacturing and clinical delivery will increase. With this increase in demand, new Current Good Manufacturing Practices (cGMP) challenges emerge.

The UK-based Asymptote makes pioneering technologies that challenge standard cell cryopreservation and thawing practices and support cGMP. The company's innovative, digitally-enabled hardware products significantly lower the risk of contamination found in conventional processes and provide exceptional control and analytics of cryochain procedures.

Ger Brophy, General Manager of GE Healthcare's Cell Therapy business said, "Asymptote's high-quality offering takes us another step forward in our vision to industrialize cell therapy, and in providing reliable and high-quality services for our customers and patients around the world. We want to improve the access to cellular therapies and tap the great potential that they have in curing some of our most difficult diseases. Finding ambitious technologies and partners like Asymptote, we are one step closer to realizing that goal."

John Morris, Founder and CEO, Asymptote Limited, said, "Asymptote is delighted to become part of GE Healthcare. Our vision, current portfolio and exciting pipeline of cryochain technology is a great fit with GE's Cell Therapy division. Our innovative range of liquid nitrogen-free controlled rate freezers are already widely used in the cryopreservation of cellular based therapies.The acquisition gives us the opportunity to reach a larger audience through the local specialist GE Cell Therapy team, provides us with a strong platform for our product launches, and allows us to significantly scale up our product development."

Asymptote's VIA FreezeTM range delivers liquid nitrogen-free cryopreservation and, soon-to-be released, VIA ThawTM series that thaws deeply frozen cells by a dry conduction (water-free) process. The company's my.Cryochain software platform synchronizes with the VIA Freeze and VIA Thaw products to standardize freezing and thawing programs across multiple sites, thereby giving improved visibility of remote processes. This web-based platform supports cell therapy companies to scale their cryopreservation and thawing processes with ease.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email

X